Novel vaccines against influenza viruses

Virus Research

Volumn 162, Issue 1-2, 2011, Pages 31-38

  Kang, S M ^a   Song, J M ^a   Compans, R W ^b  

^a GEORGIA STATE UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cross protective immunity; Influenza virus; Vaccine supplements; Vaccines

Indexed keywords

FUSION PEPTIDE VACCINE; HEMAGGLUTININ 1 VACCINE; HEMAGGLUTININ 2 VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; M2 VACCINE; M2E VACCINE; UNCLASSIFIED DRUG;

HONG KONG INFLUENZA; HUMAN; INFLUENZA A (H1N1); INFLUENZA A (H2N2); INFLUENZA A (H3N2); INFLUENZA A (H5N1); INFLUENZA VACCINATION; INFLUENZA VIRUS; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS A H5N1; INFLUENZA VIRUS B; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS INFECTIVITY;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CONSERVED SEQUENCE; CROSS PROTECTION; CROSS REACTIONS; DRUG ADMINISTRATION ROUTES; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; ORTHOMYXOVIRIDAE; PANDEMICS; PROTEIN STRUCTURE, TERTIARY; UNITED STATES; VACCINATION; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL MATRIX PROTEINS;

ORTHOMYXOVIRIDAE;

EID: 81555228636     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.09.037     Document Type: Review

References (111)

1. Al-Mazrou A., Scheifele D.W., Soong T., Bjornson G. Comparison of adverse reactions to whole-virion and split-virion influenza vaccines in hospital personnel. CMAJ 1991, 145(3):213-218.
2. Bachmann M.F., Kundig T.M., Kalberer C.P., Hengartner H., Zinkernagel R.M. Formalin inactivation of vesicular stomatitis virus impairs T-cell- but not T-help-independent B-cell responses. J. Virol. 1993, 67(7):3917-3922.
3. Bautista Rentero D., Tenias Burillo J.M., Sabater Pons A., Perez Bermudez B., Zanon Viguer V. The comparison of adverse reactions to anti-influenza vaccines of split-vision and surface antigens. Rev. Esp. Salud Publica 1995, 69(6):463-468.
4. Belshe R.B., Ambrose C.S., Yi T. Safety and efficacy of live attenuated influenza vaccine in children 2-7 years of age. Vaccine 2008, 26(SUPPL. 4):D10-D16.
5. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., Treanor J., Zangwill K., Hayden F.G., Bernstein D.I., Kotloff K., King J., Piedra P.A., Block S.L., Yan L., Wolff M. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 2000, 181(3):1133-1137.
6. Bianchi E., Liang X., Ingallinella P., Finotto M., Chastain M.A., Fan J., Fu T.M., Song H.C., Horton M.S., Freed D.C., Manger W., Wen E., Shi L., Ionescu R., Price C., Wenger M., Emini E.A., Cortese R., Ciliberto G., Shiver J.W., Pessi A. Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor. J. Virol. 2005, 79(12):7380-7388.
7. Block S.L., Yogev R., Hayden F.G., Ambrose C.S., Zeng W., Walker R.E. Shedding and immunogenicity of live attenuated influenza vaccine virus in subjects 5-49 years of age. Vaccine 2008, 26(38):4940-4946.
8. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T.M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25(19):3871-3878.
9. Bush R.M., Bender C.A., Subbarao K., Cox N.J., Fitch W.M. Predicting the evolution of human influenza A. Science 1999, 286(5446):1921-1925.
10. Cate T.R., Couch R.B., Kasel J.A., Six H.R. Clinical trials of monovalent influenza A/New Jersey/76 virus vaccines in adults: reactogenicity, antibody response, and antibody persistence. J. Infect. Dis. 1977, 136(SUPPL.):S450-S455.
11. Chen B.J., Leser G.P., Jackson D., Lamb R.A. The influenza virus M2 protein cytoplasmic tail interacts with the M1 protein and influences virus assembly at the site of virus budding. J. Virol. 2008, 82(20):10059-10070.
12. Cheung C.L., Rayner J.M., Smith G.J., Wang P., Naipospos T.S., Zhang J., Yuen K.Y., Webster R.G., Peiris J.S., Guan Y., Chen H. Distribution of amantadine-resistant H5N1 avian influenza variants in Asia. J. Infect. Dis. 2006, 193(12):1626-1629.
13. Chun S., Li C., Van Domselaar G., Wang J., Farnsworth A., Cui X., Rode H., Cyr T.D., He R., Li X. Universal antibodies and their applications to the quantitative determination of virtually all subtypes of the influenza A viral hemagglutinins. Vaccine 2008, 26(48):6068-6076.
14. Claas E.C., Osterhaus A.D., van Beek R., De Jong J.C., Rimmelzwaan G.F., Senne D.A., Krauss S., Shortridge K.F., Webster R.G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998, 351(9101):472-477.
15. Corti D., Voss J., Gamblin S.J., Codoni G., Macagno A., Jarrossay D., Vachieri S.G., Pinna D., Minola A., Vanzetta F., Silacci C., Fernandez-Rodriguez B.M., Agatic G., Bianchi S., Giacchetto-Sasselli I., Calder L., Sallusto F., Collins P., Haire L.F., Temperton N., Langedijk J.P., Skehel J.J., Lanzavecchia A. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 2011, 333(6044):850-856.
16. Davenport F.M. Current knowledge of influenza vaccine. JAMA 1962, 182:11-13.
17. De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Lowenadler B., Lycke N., Jou W.M., Saelens X. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006, 24(44-46):6597-6601.
18. De Filette M., Martens W., Roose K., Deroo T., Vervalle F., Bentahir M., Vandekerckhove J., Fiers W., Saelens X. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. J. Biol. Chem. 2008, 283(17):11382-11387.
19. De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., Resch S., Fiers W. Universal influenza A vaccine: optimization of M2-based constructs. Virology 2005, 337(1):149-161.
20. De Filette M., Ramne A., Birkett A., Lycke N., Lowenadler B., Min Jou W., Saelens X., Fiers W. The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection. Vaccine 2006, 24(5):544-551.
21. de Jong M.D., Tran T.T., Truong H.K., Vo M.H., Smith G.J., Nguyen V.C., Bach V.C., Phan T.Q., Do Q.H., Guan Y., Peiris J.S., Tran T.H., Farrar J. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N. Engl. J. Med. 2005, 353(25):2667-2672.
22. Denis J., Acosta-Ramirez E., Zhao Y., Hamelin M.E., Koukavica I., Baz M., Abed Y., Savard C., Pare C., Lopez Macias C., Boivin G., Leclerc D. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. Vaccine 2008, 26(27-28):3395-3403.
23. Ekiert D.C., Bhabha G., Elsliger M.A., Friesen R.H., Jongeneelen M., Throsby M., Goudsmit J., Wilson I.A. Antibody recognition of a highly conserved influenza virus epitope. Science 2009, 324(5924):246-251.
24. Ekiert D.C., Friesen R.H., Bhabha G., Kwaks T., Jongeneelen M., Yu W., Ophorst C., Cox F., Korse H.J., Brandenburg B., Vogels R., Brakenhoff J.P., Kompier R., Koldijk M.H., Cornelissen L.A., Poon L.L., Peiris M., Koudstaal W., Wilson I.A., Goudsmit J. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science 2011, 333(6044):843-850.
25. Eliasson D.G., Bakkouri K.E., Schon K., Ramne A., Festjens E., Lowenadler B., Fiers W., Saelens X., Lycke N. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. Vaccine 2008, 26(9):1243-1252.
26. Ernst W.A., Kim H.J., Tumpey T.M., Jansen A.D., Tai W., Cramer D.V., Adler-Moore J.P., Fujii G. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006, 24(24):5158-5168.
27. Fan J., Liang X., Horton M.S., Perry H.C., Citron M.P., Heidecker G.J., Fu T.M., Joyce J., Przysiecki C.T., Keller P.M., Garsky V.M., Ionescu R., Rippeon Y., Shi L., Chastain M.A., Condra J.H., Davies M.E., Liao J., Emini E.A., Shiver J.W. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004, 22(23-24):2993-3003.
28. Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A universal human influenza A vaccine. Virus Res. 2004, 103(1-2):173-176.
29. Forrest B.D., Pride M.W., Dunning A.J., Capeding M.R., Chotpitayasunondh T., Tam J.S., Rappaport R., Eldridge J.H., Gruber W.C. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin. Vaccine Immunol. 2008, 15(7):1042-1053.
30. Fouchier R.A., Munster V., Wallensten A., Bestebroer T.M., Herfst S., Smith D., Rimmelzwaan G.F., Olsen B., Osterhaus A.D. Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 2005, 79(5):2814-2822.
31. Fouchier R.A., Schneeberger P.M., Rozendaal F.W., Broekman J.M., Kemink S.A., Munster V., Kuiken T., Rimmelzwaan G.F., Schutten M., Van Doornum G.J., Koch G., Bosman A., Koopmans M., Osterhaus A.D. Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(5):1356-1361.
32. Frace A.M., Klimov A.I., Rowe T., Black R.A., Katz J.M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999, 17(18):2237-2244.
33. Francis T., Salk J.E., Brace W.M. The protective effect of vaccination against epidemic influenza B. JAMA 1946, 131:275-278.
34. Fu T.M., Freed D.C., Horton M.S., Fan J., Citron M.P., Joyce J.G., Garsky V.M., Casimiro D.R., Zhao Q., Shiver J.W., Liang X. Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus. Virology 2009, 385(1):218-226.
35. Fu T.M., Grimm K.M., Citron M.P., Freed D.C., Fan J., Keller P.M., Shiver J.W., Liang X., Joyce J.G. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 2009, 27(9):1440-1447.
36. Gessner J.E., Heiken H., Tamm A., Schmidt R.E. The IgG Fc receptor family. Ann. Hematol. 1998, 76(6):231-248.
37. Glaser C.A., Gilliam S., Thompson W.W., Dassey D.E., Waterman S.H., Saruwatari M., Shapiro S., Fukuda K. Medical care capacity for influenza outbreaks, Los Angeles. Emerg. Infect. Dis. 2002, 8(6):569-574.
38. Graves P.N., Schulman J.L., Young J.F., Palese P. Preparation of influenza virus subviral particles lacking the HA1 subunit of hemagglutinin: unmasking of cross-reactive HA2 determinants. Virology 1983, 126(1):106-116.
39. Harper S.A., Fukuda K., Uyeki T.M., Cox N.J., Bridges C.B. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2004, 53(RR-6):1-40.
40. Hay A.J., Wolstenholme A.J., Skehel J.J., Smith M.H. The molecular basis of the specific anti-influenza action of amantadine. EMBO J. 1985, 4(11):3021-3024.
41. Heinen P.P., Rijsewijk F.A., de Boer-Luijtze E.A., Bianchi A.T. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J. Gen. Virol. 2002, 83(Pt. 8):1851-1859.
42. Heusser C.H., Anderson C.L., Grey H.M. Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J. Exp. Med. 1977, 145(5):1316-1327.
43. Horvath A., Toth G.K., Gogolak P., Nagy Z., Kurucz I., Pecht I., Rajnavolgyi E. A hemagglutinin-based multipeptide construct elicits enhanced protective immune response in mice against influenza A virus infection. Immunol. Lett. 1998, 60(2-3):127-136.
44. Huber V.C., Lynch J.M., Bucher D.J., Le J., Metzger D.W. Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J. Immunol. 2001, 166(12):7381-7388.
45. Huber V.C., McKeon R.M., Brackin M.N., Miller L.A., Keating R., Brown S.A., Makarova N., Perez D.R., Macdonald G.H., McCullers J.A. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin. Vaccine Immunol. 2006, 13(9):981-990.
46. Huleatt J.W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., Tang J., McDonald W., Song L., Evans R.K., Umlauf S., Tussey L., Powell T.J. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008, 26(2):201-214.
47. Ionescu R.M., Przysiecki C.T., Liang X., Garsky V.M., Fan J., Wang B., Troutman R., Rippeon Y., Flanagan E., Shiver J., Shi L. Pharmaceutical and immunological evaluation of human papillomavirus viruslike particle as an antigen carrier. J. Pharm. Sci. 2006, 95(1):70-79.
48. Iwatsuki-Horimoto K., Horimoto T., Noda T., Kiso M., Maeda J., Watanabe S., Muramoto Y., Fujii K., Kawaoka Y. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J. Virol. 2006, 80(11):5233-5240.
49. Jayasekera J.P., Moseman E.A., Carroll M.C. Natural antibody and complement mediate neutralization of influenza virus in the absence of prior immunity. J. Virol. 2007, 81(7):3487-3494.
50. Jegerlehner A., Schmitz N., Storni T., Bachmann M.F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004, 172(9):5598-5605.
51. Jennings R., Smith T.L., Spencer R.C., Mellersh A.M., Edey D., Fenton P., Potter C.W. Inactivated influenza virus vaccines in man: a comparative study of subunit and split vaccines using two methods for assessment of antibody responses. Vaccine 1984, 2(1):75-80.
52. Jimenez G.S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., Lalor P., Leamy V., Vahle R., Luke C.J., Rolland A., Kaslow D.C., Smith L.R. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccin. 2007, 3(5):157-164.
53. Kashyap A.K., Steel J., Oner A.F., Dillon M.A., Swale R.E., Wall K.M., Perry K.J., Faynboym A., Ilhan M., Horowitz M., Horowitz L., Palese P., Bhatt R.R., Lerner R.A. Combinatorial antibody libraries from survivors of the Turkish H5N1 avian influenza outbreak reveal virus neutralization strategies. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(16):5986-5991.
54. Klenk H.D., Stickl H. Which influenza vaccination is the best - with whole virus, split vaccine or subunit vaccines?. Med. Welt 1981, 32(25):1008-1009.
55. Krystal M., Elliott R.M., Benz E.W., Young J.F., Palese P. Evolution of influenza A and B viruses: conservation of structural features in the hemagglutinin genes. Proc. Natl. Acad. Sci. U. S. A. 1982, 79(15):4800-4804.
56. Lalor P.A., Webby R.J., Morrow J., Rusalov D., Kaslow D.C., Rolland A., Smith L.R. Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus. J. Infect. Dis. 2008, 197(12):1643-1652.
57. Laver W.G., Air G.M., Dopheide T.A., Ward C.W. Amino acid sequence changes in the haemagglutinin of A/Hong Kong (H3N2) influenza virus during the period 1968-77. Nature 1980, 283(5746):454-457.
58. Laver W.G., Gerhard W., Webster R.G., Frankel M.E., Air G.M. Antigenic drift in type A influenza virus: peptide mapping and antigenic analysis of A/PR/8/34 (HON1) variants selected with monoclonal antibodies. Proc. Natl. Acad. Sci. U. S. A. 1979, 76(3):1425-1429.
59. Le Q.M., Kiso M., Someya K., Sakai Y.T., Nguyen T.H., Nguyen K.H., Pham N.D., Ngyen H.H., Yamada S., Muramoto Y., Horimoto T., Takada A., Goto H., Suzuki T., Suzuki Y., Kawaoka Y. Avian flu: isolation of drug-resistant H5N1 virus. Nature 2005, 437(7062):1108.
60. Li C., Jaentschke B., Song Y., Wang J., Cyr T.D., Van Domselaar G., He R., Li X. A simple slot blot for the detection of virtually all subtypes of the influenza A viral hemagglutinins using universal antibodies targeting the fusion peptide. Nat. Protoc. 2010, 5(1):14-19.
61. Liu W., Peng Z., Liu Z., Lu Y., Ding J., Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 2004, 23(3):366-371.
62. Matrosovich M.N., Matrosovich T.Y., Gray T., Roberts N.A., Klenk H.D. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol. 2004, 78(22):12665-12667.
63. McCown M.F., Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J. Virol. 2005, 79(6):3595-3605.
64. McCown M.F., Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J. Virol. 2006, 80(16):8178-8189.
65. Mostow S.R., Schoenbaum S.C., Dowdle W.R., Coleman M.T., Kaye H.S., Hierholzer J.C. Studies on inactivated influenza vaccines. II. Effect of increasing dosage on antibody response and adverse reactions in man. Am. J. Epidemiol. 1970, 92(4):248-256.
66. Mozdzanowska K., Feng J., Eid M., Zharikova D., Gerhard W. Enhancement of neutralizing activity of influenza virus-specific antibodies by serum components. Virology 2006, 352(2):418-426.
67. Mozdzanowska K., Zharikova D., Cudic M., Otvos L., Gerhard W. Roles of adjuvant and route of vaccination in antibody response and protection engendered by a synthetic matrix protein 2-based influenza A virus vaccine in the mouse. Virol. J. 2007, 4:118.
68. Murphy B.R., Coelingh K. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines. Viral Immunol. 2002, 15(2):295-323.
69. Nava G.M., Attene-Ramos M.S., Ang J.K., Escorcia M. Origins of the new influenza A(H1N1) virus: time to take action. Euro Surveill. 2009, 14(22):1-2.
70. Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W.M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999, 5(10):1157-1163.
71. Neuberger M.S., Rajewsky K. Activation of mouse complement by monoclonal mouse antibodies. Eur. J. Immunol. 1981, 11(12):1012-1016.
72. Ohmit S.E., Victor J.C., Teich E.R., Truscon R.K., Rotthoff J.R., Newton D.W., Campbell S.A., Boulton M.L., Monto A.S. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. J. Infect. Dis. 2008, 198(3):312-317.
73. Okuno Y., Isegawa Y., Sasao F., Ueda S. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J. Virol. 1993, 67(5):2552-2558.
74. Palache A.M., Beyer W.E., Luchters G., Volker R., Sprenger M.J., Masurel N. Influenza vaccines: the effect of vaccine dose on antibody response in primed populations during the ongoing interpandemic period. A review of the literature. Vaccine 1993, 11(9):892-908.
75. Palese P., Compans R.W. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J. Gen. Virol. 1976, 33(1):159-163.
76. Peiris M., Yuen K.Y., Leung C.W., Chan K.H., Ip P.L., Lai R.W., Orr W.K., Shortridge K.F. Human infection with influenza H9N2. Lancet 1999, 354(9182):916-917.
77. Plotkin J.B., Dushoff J. Codon bias and frequency-dependent selection on the hemagglutinin epitopes of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(12):7152-7157.
78. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., Bridges C.B., Grijalva C.G., Zhu Y., Bernstein D.I., Herrera G., Erdman D., Hall C.B., Seither R., Griffin M.R. The underrecognized burden of influenza in young children. N. Engl. J. Med. 2006, 355(1):31-40.
79. Prabhu N., Prabakaran M., Ho H.T., Velumani S., Qiang J., Goutama M., Kwang J. Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5N1 infection. J. Virol. 2009, 83(6):2553-2562.
80. Quinnan G.V., Schooley R., Dolin R., Ennis F.A., Gross P., Gwaltney J.M. Serologic responses and systemic reactions in adults after vaccination with monovalent A/USSR/77 and trivalent A/USSR/77, A/Texas/77, B/Hong Kong/72 influenza vaccines. Rev. Infect. Dis. 1983, 5(4):748-757.
81. Robertson J.S., Nicolson C., Newman R., Major D., Dunleavy U., Wood J.M. High growth reassortant influenza vaccine viruses: new approaches to their control. Biologicals 1992, 20(3):213-220.
82. Sagawa H., Ohshima A., Kato I., Okuno Y., Isegawa Y. The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region. J. Gen. Virol. 1996, 77(Pt. 7):1483-1487.
83. Salk J.E., Pearson H.E., Brown P.N., Francis T. Protective effect of vaccination against induced influenza B. J. Clin. Invest. 1945, 24(4):547-553.
84. Schnell J.R., Chou J.J. Structure and mechanism of the M2 proton channel of influenza A virus. Nature 2008, 451(7178):591-595.
85. Slepushkin V.A., Katz J.M., Black R.A., Gamble W.C., Rota P.A., Cox N.J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995, 13(15):1399-1402.
86. Solovyov A., Palacios G., Briese T., Lipkin W.I., Rabadan R. Cluster analysis of the origins of the new influenza A(H1N1) virus. Euro Surveill. 2009, 14(21):1-50.
87. Song J.M., Van Rooijen N., Bozja J., Compans R.W., Kang S.M. Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus. Proc. Natl. Acad. Sci. U. S. A. 2011, 108(2):757-761.
88. Song J.M., Wang B.Z., Park K.M., Van Rooijen N., Quan F.S., Kim M.C., Jin H.T., Pekosz A., Compans R.W., Kang S.M. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 2011, 6(1):e14538.
89. Steel J., Lowen A.C., Wang T., Yondola M., Gao Q., Haye K., Garcia-Sastre A., Palese P. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio 2010, 1(1):1-9.
90. Stokes J., Chenoweth A.D., Waltz A.D., Gladen R.G., Shaw D. Results of immunization by means of active virus of human influenza. J. Clin. Invest. 1937, 16(2):237-243.
91. Stouffer A.L., Acharya R., Salom D., Levine A.S., Di Costanzo L., Soto C.S., Tereshko V., Nanda V., Stayrook S., DeGrado W.F. Structural basis for the function and inhibition of an influenza virus proton channel. Nature 2008, 451(7178):596-599.
92. Subbarao K., Klimov A., Katz J., Regnery H., Lim W., Hall H., Perdue M., Swayne D., Bender C., Huang J., Hemphill M., Rowe T., Shaw M., Xu X., Fukuda K., Cox N. Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. Science 1998, 279(5349):393-396.
93. Sui J., Hwang W.C., Perez S., Wei G., Aird D., Chen L.M., Santelli E., Stec B., Cadwell G., Ali M., Wan H., Murakami A., Yammanuru A., Han T., Cox N.J., Bankston L.A., Donis R.O., Liddington R.C., Marasco W.A. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 2009, 16(3):265-273.
94. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Bridges C.B., Cox N.J., Fukuda K. Influenza-associated hospitalizations in the United States. JAMA 2004, 292(11):1333-1340.
95. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N., Anderson L.J., Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003, 289(2):179-186.
96. Tompkins S.M., Zhao Z.S., Lo C.Y., Misplon J.A., Liu T., Ye Z., Hogan R.J., Wu Z., Benton K.A., Tumpey T.M., Epstein S.L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007, 13(3):426-435.
97. Treanor J.J., Tierney E.L., Zebedee S.L., Lamb R.A., Murphy B.R. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 1990, 64(3):1375-1377.
98. Wang R., Song A., Levin J., Dennis D., Zhang N.J., Yoshida H., Koriazova L., Madura L., Shapiro L., Matsumoto A., Mikayama T., Kubo R.T., Sarawar S., Cheroutre H., Kato S. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res. 2008, 80(2):168-177.
99. Wang T.T., Tan G.S., Hai R., Pica N., Ngai L., Ekiert D.C., Wilson I.A., Garcia-Sastre A., Moran T.M., Palese P. Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc. Natl. Acad. Sci. U. S. A. 2010, 107(44):18979-18984.
100. Wang T.T., Tan G.S., Hai R., Pica N., Petersen E., Moran T.M., Palese P. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog. 2010, 6(2):e1000796.
101. Wei C.J., Boyington J.C., McTamney P.M., Kong W.P., Pearce M.B., Xu L., Andersen H., Rao S., Tumpey T.M., Yang Z.Y., Nabel G.J. Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 2010, 329(5995):1060-1064.
102. Wilson I.A., Skehel J.J., Wiley D.C. Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution. Nature 1981, 289(5796):366-373.
103. Wong S.S., Yuen K.Y. Avian influenza virus infections in humans. Chest 2006, 129(1):156-168.
104. Wrammert J., Koutsonanos D., Li G.M., Edupuganti S., Sui J., Morrissey M., McCausland M., Skountzou I., Hornig M., Lipkin W.I., Mehta A., Razavi B., Del Rio C., Zheng N.Y., Lee J.H., Huang M., Ali Z., Kaur K., Andrews S., Amara R.R., Wang Y., Das S.R., O'Donnell C.D., Yewdell J.W., Subbarao K., Marasco W.A., Mulligan M.J., Compans R., Ahmed R., Wilson P.C. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 2011, 208(1):181-193.
105. Wright P., Webster R. Orthomyxoviruses. Fields Virology 2001, vol. 2:1533-1579. Lippncott Williams & Wilkins Press, Philadelphia. 4th ed.
106. Wright P.F., Cherry J.D., Foy H.M., Glezen W.P., Hall C.B., McIntosh K., Monto A.S., Parrott R.H., Portnoy B., Taber L.H. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children - a multicentered evaluation of dosage and safety. Rev. Infect. Dis. 1983, 5(4):758-764.
107. Wu F., Huang J.H., Yuan X.Y., Huang W.S., Chen Y.H. Characterization of immunity induced by M2e of influenza virus. Vaccine 2007, 25(52):8868-8873.
108. Wu F., Yuan X.Y., Huang W.S., Chen Y.H. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine. Vaccine 2009, 27(43):6095-6101.
109. Wu F., Yuan X.Y., Li J., Chen Y.H. The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine. Vaccine 2009, 27(32):4320-4324.
110. Zebedee S.L., Lamb R.A. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J. Virol. 1988, 62(8):2762-2772.
111. Zhao G., Du L., Xiao W., Sun S., Lin Y., Chen M., Kou Z., He Y., Lustigman S., Jiang S., Zheng B.J., Zhou Y. Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine 2010, 28(44):7233-7240.